OBX short interest jumps 249.5% as shares sit near 52-week low
Alpha Vantage · MarketBeat · · AI-summarised by FinFlash
Obsidian Therapeutics (NASDAQ:OBX) experienced a significant 249.5% surge in short interest in September, reaching 884,528 shares. Despite this, analysts maintain a "Moderate Buy" rating with an average target price of $39.00. The company, which focuses on engineered cell and gene therapies, saw its shares trade at Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context